Quest for the right Drug
מסנה-סל 100 מ"ג/מ"ל MESNA-CELL 100 MG/ML (MESNA)
תרופה במרשם
תרופה בסל
נרקוטיקה
ציטוטוקסיקה
צורת מתן:
תוך-ורידי : I.V
צורת מינון:
תמיסה להזרקה : SOLUTION FOR INJECTION
עלון לרופא
מינוניםPosology התוויות
Indications תופעות לוואי
Adverse reactions התוויות נגד
Contraindications אינטראקציות
Interactions מינון יתר
Overdose הריון/הנקה
Pregnancy & Lactation אוכלוסיות מיוחדות
Special populations תכונות פרמקולוגיות
Pharmacological properties מידע רוקחי
Pharmaceutical particulars אזהרת שימוש
Special Warning עלון לרופא
Physicians Leaflet
Adverse reactions : תופעות לוואי
4.8 Undesirable effects In this section frequencies of undesirable effects are defined as follows: Very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000); not known (cannot be estimated from the available data). Commonly the occurrence of anaphylactoid and other hyperergic reactions have been reported, e.g. in some cases in connection with the reduction of the thrombocyte count, were reported after the use of mesna. This risk is approx. 3.5 times higher in patients with autoimmune disease than in patients with tumour disease (without autoimmune disease). Skin and mucous membrane reactions, such as urticaria, itching, exanthema up to the formation of blisters, enanthema, Lyell’s syndrome, Stevens-Johnson syndrome, local tissue swellings, conjunctivitis as well as unspecific general symptoms such as fever, chills, face redness, cough, pharyngitis, fatigue, tiredness, headache, back pain, arthralgia, nausea and vomiting, flatulence, diarrhoea, constipation, colics (e.g. abdominal pain), anorexia, influenza-like symptoms occurred. Circulatory reactions such as a drop in blood pressure and tachycardia (pulse rate >100/min), tachypnoea, hypertension, ST-segment elevation and myalgia and also a transient increase of values of different liver function tests (such as e.g transaminases) were observed. Uncommonly, local oedema and venous irritation at the injection site occurred. In a tolerability study with high intravenous or oral doses of mesna, nausea, vomiting, diarrhoea, headache, limb and joint pain, drop in blood pressure and tachycardia, skin reactions, exhaustion, weakness, depression, irritability and exanthema occurred, when a single dose of 60 mg/kg body weight was administered. During treatment, the undesirable effects mentioned above cannot always be distinguished from those of the oxazaphosphorines or other concomitant medication. SOC Common Uncommon Rare Very rare Infections and Pharyngitis infestations Immune system Hypersensitivity Anaphylactoid disorders reactions, reactions, allergic hyperergic reactions reactions Metabolism and Anorexia nutrition disorders Psychiatric Irritability, disorders depression Nervous system Headache disorders Eye disorders Conjunctivitis Cardiac disorders Tachycardia Vascular disorders Drop in blood pressure, hypertension, face redness, circulatory reactions SOC Common Uncommon Rare Very rare Respiratory, Tachypnoea, thoracic and cough mediastinal disorders Gastrointestinal Nausea, vomiting Diarrhoea Flatulence, disorders constipation, colics, abdominal pain Skin and Itching, Urticaria Stevens-Johnson subcutaneous exanthema, syndrome, Lyell’s tissue disorders enanthematous syndrome skin reactions Musculoskeletal Local tissue Back pain Arthralgia, and connective swelling Myalgia, limb tissue disorders pain, joint pain General disorders Fever Local oedema, Exhaustion, Influenza-like and administration venous irritation weakness, symptoms site conditions at the injection mucous skin site, chills reactions, fatigue, tiredness Investigations Increase of the Reduction of the values of different thrombocyte liver function tests count, pulse rate > 100/min, ST- segment elevation Injury, poisoning Toxic reactions and procedural complications Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Any suspected adverse events should be reported to the Ministry of Health according to the National Regulation by using an online form https://sideeffects.health.gov.il
שימוש לפי פנקס קופ''ח כללית 1994
לא צוין
תאריך הכללה מקורי בסל
לא צוין
הגבלות
לא צוין
מידע נוסף